On Monday, Pyxis Oncology Inc (NASDAQ: PYXS) opened higher 7.74% from the last session, before settling in for the closing price of $3.36. Price fluctuations for PYXS have ranged from $1.35 to $6.85 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Company’s average yearly earnings per share was noted 45.05% at the time writing. With a float of $46.32 million, this company’s outstanding shares have now reached $58.94 million.
In an organization with 50 employees, it is important to assess its efficiency. In terms of profitability, gross margin is 81.52%, operating margin of -351.42%, and the pretax margin is -302.58%.
Pyxis Oncology Inc (PYXS) Insider Updates
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of Pyxis Oncology Inc is 21.42%, while institutional ownership is 52.77%. The most recent insider transaction that took place on Sep 28 ’23, was worth 14,960. In this transaction CFO and COO of this company bought 8,000 shares at a rate of $1.87, taking the stock ownership to the 818,532 shares. Before that another transaction happened on Sep 27 ’23, when Company’s Chief Accounting Officer bought 2,500 for $1.87, making the entire transaction worth $4,675. This insider now owns 226,937 shares in total.
Pyxis Oncology Inc (PYXS) Performance Highlights and Predictions
According to the Wall Street analysts, stocks earnings will be around 45.05% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 34.60% during the next five years compared to -118.72% drop over the previous five years of trading.
Pyxis Oncology Inc (NASDAQ: PYXS) Trading Performance Indicators
Check out the current performance indicators for Pyxis Oncology Inc (PYXS). In the past quarter, the stock posted a quick ratio of 9.53. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 13.21.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.26, a number that is poised to hit -0.32 in the next quarter and is forecasted to reach -1.17 in one year’s time.
Technical Analysis of Pyxis Oncology Inc (PYXS)
Let’s dig in a bit further. During the last 5-days, its volume was 0.55 million. That was inferior than the volume of 0.68 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 61.67%. Additionally, its Average True Range was 0.30.
During the past 100 days, Pyxis Oncology Inc’s (PYXS) raw stochastic average was set at 24.04%, which indicates a significant decrease from 54.17% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 86.73% in the past 14 days, which was higher than the 72.54% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $3.43, while its 200-day Moving Average is $3.54. However, in the short run, Pyxis Oncology Inc’s stock first resistance to watch stands at $3.76. Second resistance stands at $3.90. The third major resistance level sits at $4.11. If the price goes on to break the first support level at $3.41, it is likely to go to the next support level at $3.20. Assuming the price breaks the second support level, the third support level stands at $3.06.
Pyxis Oncology Inc (NASDAQ: PYXS) Key Stats
There are currently 58,888K shares outstanding in the company with a market cap of 213.36 million. Presently, the company’s annual sales total 0 K according to its annual income of -73,790 K. Last quarter, the company’s sales amounted to 16,150 K and its income totaled -3,260 K.
